Aquestive provides business update; on track to submit Anaphylm NDA in Q1 2025; cash ~$70M

Aquestive Therapeutics, Inc.

On track to submit Anaphylm (epinephrine) Sublingual Film NDA to FDA in Q1 2025; potential approval/launch as early as Q1 2026.
Successfully completed pre-IND meeting for AQST-108 (epinephrine) Topical Gel; Phase 2a in alopecia areata to begin Q2 2025.
Unaudited cash and cash equivalents approximately $70 million as of Dec 31, 2024.
Libervant (diazepam) Buccal Film received FDA approval for ages 2-5 and Orphan Drug Exclusivity until April 2031.
CEO outlines 2025 focus: Anaphylm launch prep, ex-U.S. strategy, AQST-108 Phase 2a, Libervant expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.